Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant treatment for high risk melanoma. Where are we now?

  • Review
  • Published:
Oncology Reviews

Abstract

The survival rate for stage 3 and 4 melanoma is very poor. In the absence of effective treatments for metastatic disease focus has shifted to the adjuvant setting. While we are now able to identify those who are at high risk of recurrence the role of adjuvant systemic treatment in these individuals is still undefined. This is partly due to the lack of effective treatments, despite the advances in the understanding of the biology of melanoma and the natural history of the disease process. Of the various treatments studied in the adjuvant setting only interferons and vaccines have been shown to affect the clinical outcome but no agent has been accepted as a standard, with differences in practice between the US and Europe. In this review article we will report what is known at this time about the different agents studied in the adjuvant setting and refer to some new areas of research that may play a bigger role in the future management of melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Welch H, Woloshin, Schwartz LM (2005) Skin biopsy rates and incidence of melanoma: population based ecological study. Br Med J 331:481

    Article  Google Scholar 

  2. Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648

    PubMed  CAS  Google Scholar 

  3. Hayes AJ, Clark MA, Harries M et al (2004) Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg 91:673–682

    Article  PubMed  CAS  Google Scholar 

  4. Greene F, Page D, Fleming I et al (2002) AJCC Staging Manual 6th edition. Springer

  5. Griffiths CEM (1999) The British Association of Dermatologists guidelines for the management of skin disease. Br J Dermatol; 141:396–397

    Article  PubMed  Google Scholar 

  6. Mc Govern VJ (1982) Spontaneous regression of malignant melanoma. In: (ed. A. Blaustein) Melanoma: Histological diagnosis and prognosis New York: Raven Press 138–147

    Google Scholar 

  7. Rosenberg SA, Yannelli JR, Yang JC et al (1994) Treatment of patients with metastatic melanoma with autologous tumour infiltrating lymphocytes and Interleukin 2. J Natl Cancer Inst 86:1159

    Article  PubMed  CAS  Google Scholar 

  8. Faries MB, Morton DL (2005) Therapeutic vaccines for melanoma: current status. Biodrugs 19:247–260

    Article  PubMed  CAS  Google Scholar 

  9. Bart RS, Porzio NR, Kopf AW et al (1980) Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res 40:614–619

    PubMed  CAS  Google Scholar 

  10. Kirkwood JM, Strawderman MH, Erstoff MS et al (1996) Interferon Alfa 2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7–17

    PubMed  CAS  Google Scholar 

  11. Kleeberg UR, Brocker EB, Lejeune F (1999) Adjuvant trial in melanoma patients comparing rIFN-alfa to rIFN-gamma to Iscador to a control group after curative resection of high risk primary or regional lymph node metastasis (EORTC 18871). Eur J Cancer 35[Suppl 4]:S82

    Article  Google Scholar 

  12. Edward F McClay (2002) Adjuvant therapy for patients with high risk malignant melanoma. Semin Oncol 29:389–399

    Article  Google Scholar 

  13. Kirkwood JM, Ibrahim JG, Sosman JA et al. High and low dose interferon alpha-2b in high risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol 18:2444–2458

  14. Kirkwood JM, Ibrahim JG, Sosman JA et al. High dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage 2B-3 melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 19:2370–2380

  15. Kirkwood JM, Ibrahim J, Lawson DH et al (2001) High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19:1430–1436

    PubMed  CAS  Google Scholar 

  16. Gogas H, Dafni U, Bafaloukos A et al (2007) A randomised phase 3 trial of 1 month versus 1 year adjuvant high dose interferon alpha-2b in patients with resected high risk melanoma. Proc Am Soc Clin Oncol 25[Suppl 18]:8505

    Google Scholar 

  17. Cascinelli N (1995) Evaluation of efficacy of adjuvant rIFN alpha-2a in melanoma patients with regional node metastases (Abstract). Proc Am Soc Clin Oncol 14:410

    Google Scholar 

  18. Grob JJ, Dreno B, de la Salmoniere P et al (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 35:1905–1920

    Article  Google Scholar 

  19. Pehamberger H, Soyer HP, Steiner A et al (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16:1425–1429

    PubMed  CAS  Google Scholar 

  20. Creagan ET, Dalton RJ, Ahmann DL et al (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776–2783

    PubMed  CAS  Google Scholar 

  21. Meyskens FK Jr, Kopecky KJ, Taylor CW et al (1995) Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst 87:1710–1713

    Article  PubMed  Google Scholar 

  22. Hancock BW, Wheatley K, Harris S et al (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma. J Clin Oncol 22:53–61

    Article  PubMed  CAS  Google Scholar 

  23. Kirkwood JM, Manola J, Ibrahim J et al (2004) A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high dose interferon. Clin Cancer Res 10:1670–1677

    Article  PubMed  CAS  Google Scholar 

  24. Fay J, Paluka AK, Paczesny S et al (2006) Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells. Cancer Immunol Immunother 55:1209–1218

    Article  PubMed  CAS  Google Scholar 

  25. Boon T et al (2004) Correlation between tumour regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 101 [Suppl]:14631–14638

    Article  PubMed  Google Scholar 

  26. Van Epps D (2004) Characterization of polyvalent allogenic vaccines. Dev Biol (Basel) 116:79–11690

    Google Scholar 

  27. Cheever MA, Henderson RA, Mossman S et al (2005) Cancer Vaccines and immunotherapies: emerging perspectives. Vaccine 23:2359–2362

    Article  PubMed  CAS  Google Scholar 

  28. Eggermont A (2007) Randomized trials in melanoma: an update. Surg Oncol Clin N Am 15:439–451

    Article  Google Scholar 

  29. Takahashi H, Johnson TD, Nishinaka Y et al (1999) IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 112:205

    Article  PubMed  CAS  Google Scholar 

  30. Spitler LE (1991) A Randomised trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 9:736–740

    PubMed  CAS  Google Scholar 

  31. Lejeune FJ, Macher E, Kleeberg U et al (1988) An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase II adjuvant study (EORTC 18761). Eur J Cancer 24:S81–S90

    Google Scholar 

  32. Spitler LE, Grossbard ML, Ernstoff MS et al (2000) Adjuvant therapy of stage III and IV melanoma using granulocyte-macrophage colony stimulating factor. J Clin Oncol 18:1614–1621.

    PubMed  CAS  Google Scholar 

  33. Randomised Control trial of adjuvant chemo immunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983;128:929

  34. Carbone PP, Costello W (1976) Eastern Cooperative Oncological Group studies with DTIC. Cancer Treat Rep 60:193–198

    PubMed  CAS  Google Scholar 

  35. Legha SS (1989) Current therapy for malignant melanoma. Semin Oncol 16:34–44

    PubMed  CAS  Google Scholar 

  36. Pectasides D, Alevizakos N, Bafaloukos D (1994) Adjuvant chemotherapy with vindesine, dacarbazine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol 17:55–59

    Article  PubMed  CAS  Google Scholar 

  37. Knost JA, Reynolds V, Greco MD et al (1982) Adjuvant chemioimmunotherapy stage I/II malignant melanoma. J Surg Oncol 19:123–187

    Article  Google Scholar 

  38. Koops HS, Vaglini M, Suciu S et al (1998) Prophylactic isolated limb perfusion for localised, high risk limb melanoma: results of a multi centre randomised phase III trial. European Organisation for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, The World Health Organisation Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 16:2906–2912

    PubMed  CAS  Google Scholar 

  39. Corry J, Smith JG, Bishop M et al (1999) Nodal radiation therapy for metastatic melanoma. Int J Radiat Oncol Biol Phys 44:1065–1069

    PubMed  CAS  Google Scholar 

  40. Bastiaanet E, Beukema JC, Hoekstra HJ (2005) Radiation Therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev 31:18–26

    Article  Google Scholar 

  41. Ballo MT, Strom MD, Zagars GK et al (2002) Adjuvant radiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 52:964–972

    PubMed  Google Scholar 

  42. Creagan ET, Cupps RE, Ivins JC et al (1978) Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. Cancer 42:2206–2210

    Article  PubMed  CAS  Google Scholar 

  43. Fife K, Thompson JF (2001) Lymph-node metastases in patients with melanoma: what is the optimum management. Lancet Oncol 2:614–621

    Article  PubMed  CAS  Google Scholar 

  44. Ang KK, Byers RM, Peters LJ et al (1990) Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Arch Otolaryngol Head Neck Surg 116:169

    PubMed  CAS  Google Scholar 

  45. http://www.trog.com.au

  46. Kefford RF (2003) Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 14:358–365

    Article  PubMed  CAS  Google Scholar 

  47. Danson S, Lorigan P (2006) Melanoma vaccines — they should work. Ann Oncol 17:539–541

    Article  PubMed  CAS  Google Scholar 

  48. Stam-Posthuma JJ, Duinen C Van, Scheffer E et al (2001) Multiple primary melanomas. J Am Acad Dermatol 44:22–27

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The Royal Marsden Hospital Foundation Trust, Fulham Road, London, UK

    Anand Sharma

  2. Department of Medical Oncology, Velindre Cancer Centre, Cardiff, UK

    Tahir Abbas & Sarah Gwynne

Authors
  1. Anand Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tahir Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah Gwynne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anand Sharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, A., Abbas, T. & Gwynne, S. Adjuvant treatment for high risk melanoma. Where are we now?. Oncol Rev 2, 53–60 (2008). https://doi.org/10.1007/s12156-008-0056-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12156-008-0056-2

Keywords

Search

Navigation